{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Minimal Residual Disease (MRD)-negative complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Stringent complete response (sCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"}]}],"title":"Very good partial response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"}]}],"title":"Partial response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"}]}],"title":"Minimal response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"86"},{"groupId":"OG004","value":"45"}]}],"title":"Stable disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"36"}]}],"title":"Progressive disease (DP)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"BOR consisted of MRD-negative CR,sCR,CR,VGPR,PR,MR,SD \\& PD per 2016 IMWG. MRD: evaluated using adaptive next generation sequencing(NGS) for MRD assay \\& carried out on relevant specimen to understand activity of SEA-BCMA. sCR: CR \\& normal FLC ratio \\& absence of clonal cells in bone marrow by IC/ IF. CR: Negative immunofixation of serum \\& urine disappearance of any STP, \\& \\<5% plasma cells in bone marrow. VGPR: SMP \\& UMP detectable by IF but not on electrophoresis/ \\>= 90% reduction(R) in SMP level+UMP level \\<100 mg/24 hr, PR: \\>=50% R of SMP \\& R in 24-hr UMP by \\>=90%/by \\<200 mg/24 hr. If SMP \\& UMP are unmeasurable, \\>=50% decrease in difference between involved \\& uninvolved FLC levels were required in place of M-protein criteria. SD: Not meeting criteria for CR, VGPR, PR, MR, or progression. MR: 25-49% R of SMP \\& R in 24-hr UMP by 50-89%, which still exceeds 200mg/24 hr. DP: objective evidence of tumor progression(based on serum/urine/BM assessments) \\&/clinical progression/investigator.","groups":[{"description":"Participants received SEA-BCMA 100 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part A: SEA-BCMA 100mg"},{"description":"Participants received SEA-BCMA 200 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG001","title":"Part A: SEA-BCMA 200mg"},{"description":"Participants received SEA-BCMA 400 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG002","title":"Part A: SEA-BCMA 400mg"},{"description":"Participants received SEA-BCMA 800 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG003","title":"Part A: SEA-BCMA 800mg"},{"description":"Participants received SEA-BCMA 1600 mg as a monotherapy q2wk IV on Day 1 and 15 of each 28- day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG004","title":"Part A: SEA-BCMA 1600mg"}],"paramType":"NUMBER","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 45 months)","title":"Percentage of Participants With Best Overall Response (BOR) as Per the IMWG Uniform Response Criteria: Part A","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}